Filing Flows › Enanta Pharmaceuticals (ENTA) › Q2 FY26 › vs Q1 FY26
Enanta Pharmaceuticals (ENTA) Q2 FY26 vs Q1 FY26 (quarter over quarter)
Enanta Pharmaceuticals's revenue fell $1.5M (-8%) from $18.6M in Q1 FY26 to $17.2M in Q2 FY26.
Enanta Pharmaceuticals, Q2 FY26: revenue $17.2M (+15% year over year), operating margin -69.1%, net loss $13.1M, operating cash flow −$7.2M. The chart draws each line against Q1 FY26, the increases inside each band.
Every line
| Line | Q2 FY26 | Q1 FY26 | Change | % |
|---|---|---|---|---|
| Revenue | $17.2M | $18.6M | −$1.5M | -8% |
| Net loss | $13.1M | $11.9M | $1.2M | +10% |
| Costs & expenses | $30.2M | $30.6M | −$303K | -1% |
| Operating costs | $29.0M | $29.9M | −$857K | -3% |
| Interest & other, net | $1.2M | $661K | $571K | +86% |
| Income tax | $7K | $24K | −$17K | -71% |
| Research & development | $19.4M | $20.9M | −$1.4M | -7% |
| General & admin | $9.6M | $9.0M | $559K | +6% |
| Operating cash sources | $13.1M | $11.9M | $1.2M | +10% |
| Depreciation & amortization | $1.2M | $1.2M | −$21K | -2% |
| Share-based compensation | $3.7M | $3.8M | −$62K | -2% |
| Working capital & other | $978K | −$4.8M | $5.8M | — |
| Cash used in operations | $7.2M | $11.7M | −$4.5M | -39% |
| Net loss absorbed | $13.1M | $11.9M | $1.2M | +10% |
Questions
How much did Enanta Pharmaceuticals's revenue grow quarter over quarter in Q2 FY26?
Enanta Pharmaceuticals's revenue fell $1.5M (-8%) from $18.6M in Q1 FY26 to $17.2M in Q2 FY26.